InvestorRoom | Kitov Pharmaceuticals Kitov to Host Business Update Conference Call on Monday, July 2 Wed, 27 Jun 2018 03:23:00 -0400 Kitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy Results in PDX model of pancreatic cancer supports planned IND for NT219 Fri, 15 Jun 2018 09:31:00 -0400 Kitov Announces Pricing of $8,150,000 Registered Direct Offering Fri, 01 Jun 2018 08:40:00 -0400 FDA Approves Kitov’s Consensi™ for Treatment of Osteoarthritis Pain and Hypertension New drug choice for millions of Americans offers one pill for treatment of osteoarthritis pain with a built-in antihypertensive Thu, 31 May 2018 13:45:00 -0400 Kitov Announces Consensi™ Commercialization Agreement for China Kitov to receive milestone payments of up to $9.5 million, as well as potential double-digit royalties Fri, 11 May 2018 08:30:00 -0400